BRIEF published on 11/26/2025 at 00:51, 1 month 15 days ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 1 month 15 days ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 1 month 17 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 1 month 17 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 4 months 27 days ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
PRESS RELEASE published on 08/15/2025 at 13:27, 4 months 27 days ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 5 months 3 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 5 months 3 days ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 6 months 17 days ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 6 months 17 days ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
Published on 01/10/2026 at 05:10, 1 day 18 hours ago Sekur Private Data Ltd. Announces Non-Brokered Private Placement
Published on 01/10/2026 at 00:45, 1 day 22 hours ago Digi Power X Announces Entry into Settlement Agreement
Published on 01/09/2026 at 23:30, 2 days ago Matador Technologies Announces Grant of Restricted Share Units to Management Team
Published on 01/09/2026 at 23:10, 2 days ago Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction
Published on 01/11/2026 at 22:20, 1 hour 12 minutes ago Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Published on 01/10/2026 at 21:25, 1 day 2 hours ago CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
Published on 01/10/2026 at 13:05, 1 day 10 hours ago SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation
Published on 01/09/2026 at 21:55, 2 days 1 hour ago Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Published on 01/09/2026 at 18:36, 2 days 4 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/09/2026 at 18:30, 2 days 5 hours ago H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm
Published on 01/09/2026 at 17:45, 2 days 5 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 01/09/2026 at 17:42, 2 days 5 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 December 2025
Published on 01/08/2026 at 21:00, 3 days 2 hours ago Biannual report on SEB S.A.’S liquidity agreement
